Skip to content
10-K

Annual Report

DRUGS MADE IN AMERICA ACQUISITION CORP. DMAA DMAAR DMAAU

0001213900-26-044139

← back to feed
Filed
Apr 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Apr 15, 2026 33.72M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$539.19K
Operating Cash Flow FY 2025 · Dec 31, 2024 −$172.27K
Stockholders Equity FY 2025 · Dec 31, 2025 −$7.26M
Stockholders Equity FY 2025 · Dec 31, 2024 −$244.85K
Current Liabilities FY 2025 · Dec 31, 2025 $376.17K
Current Liabilities FY 2025 · Dec 31, 2024 $795.67K
Total Liabilities FY 2025 · Dec 31, 2025 $7.28M
Total Liabilities FY 2025 · Dec 31, 2024 $795.67K
Current Assets FY 2025 · Dec 31, 2025 $12.19K
Current Assets FY 2025 · Dec 31, 2024 $4.99K
Total Assets FY 2025 · Dec 31, 2025 $239.92M
Total Assets FY 2025 · Dec 31, 2024 $550.82K
Sga Expense FY 2025 · Dec 31, 2025 $2.82M
Sga Expense FY 2025 · Dec 31, 2024 $279.85K
Net Income FY 2025 · Dec 31, 2025 $5.94M
Net Income FY 2025 · Dec 31, 2024 −$279.85K
Operating Income FY 2025 · Dec 31, 2025 −$2.82M
Operating Income FY 2025 · Dec 31, 2024 −$279.85K